Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.10    
    

 
 

INDEMNIFICATION AGREEMENT    

        This
Agreement made and entered into this      day of                  2007 (the "Agreement"), by and between Helicos BioSciences
Corporation, a Delaware corporation (the
"Company," which term shall include, where appropriate, any Entity (as hereinafter defined) controlled directly or indirectly by the Company)
and                        (the "Indemnitee"): 

        WHEREAS,
it is essential to the Company that it be able to retain and attract as directors the most capable persons available; 

        WHEREAS,
increased corporate litigation has subjected directors to litigation risks and expenses, and the limitations on the availability of directors and officers liability insurance
have made it increasingly difficult for the Company to attract and retain such persons; 

        WHEREAS,
the Company's By-laws (the "By-laws") require it to indemnify its directors to the fullest extent permitted by law and permit it to make other
indemnification arrangements and agreements; 

        WHEREAS,
the Company desires to provide Indemnitee with specific contractual assurance of Indemnitee's rights to full indemnification against litigation risks and expenses (regardless,
among other things, of any amendment to or revocation of the By-laws or any change in the ownership of the Company or the composition of its Board of Directors); 

        WHEREAS,
the Company intends that this Agreement provide Indemnitee with greater protection than that which is provided by the Company's By-laws; and 

        WHEREAS,
Indemnitee is relying upon the rights afforded under this Agreement in becoming or continuing as a director of the Company. 

        NOW,
THEREFORE, in consideration of the promises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows: 

        1.    Definitions.    

        (a)   "Corporate
Status" describes the status of a person who is serving or has served (i) as a director of the Company, (ii) in any capacity with respect to any
employee benefit plan of the Company, or (iii) as a director, partner, trustee, officer, employee, or agent of any other Entity at the request of the Company. For purposes of subsection
(iii) of this Section 1(a), if Indemnitee is serving or has served as a director, partner, trustee, officer, employee or agent of a Subsidiary, Indemnitee shall be deemed to be serving
at the request of the Company. 

        (b)   "Entity"
shall mean any corporation, partnership, limited liability company, joint venture, trust, foundation, association, organization or other legal entity. 

        (c)   "Expenses"
shall mean all fees, costs and expenses incurred by Indemnitee in connection with any Proceeding (as defined below), including, without limitation, attorneys'
fees, disbursements and retainers (including, without limitation, any such fees, disbursements and retainers incurred by Indemnitee pursuant to Sections 10 and 11(c) of this Agreement), fees
and disbursements of expert witnesses, private investigators and professional advisors (including, without limitation, accountants and investment bankers), court costs, transcript costs, fees of
experts, travel expenses, duplicating, printing and binding costs, telephone and fax transmission charges, postage, delivery services, secretarial services, and other disbursements and expenses. 

        (d)   "Indemnifiable
Expenses," "Indemnifiable Liabilities" and "Indemnifiable Amounts" shall have the meanings ascribed to those terms in Section 3(a) below. 

        (e)   "Liabilities"
shall mean judgments, damages, liabilities, losses, penalties, excise taxes, fines and amounts paid in settlement. 

 

        (f)    "Proceeding"
shall mean any threatened, pending or completed claim, action, suit, arbitration, alternate dispute resolution process, investigation, administrative
hearing, appeal, or any other proceeding, whether civil, criminal, administrative, arbitrative or investigative, whether formal or informal, including a proceeding initiated by Indemnitee pursuant to
Section 10 of this Agreement to enforce Indemnitee's rights hereunder. 

        "Subsidiary"
shall mean any corporation, partnership, limited liability company, joint venture, trust or other Entity of which the Company owns (either directly or through or together
with another Subsidiary of the Company) either (i) a general partner, managing member or other similar interest or (ii) (A) 50% or more of the voting power of the voting capital
equity interests of such corporation, partnership, limited liability company, joint venture or other Entity, or (B) 50% or more of the outstanding voting capital stock or other voting equity
interests of such corporation, partnership, limited liability company, joint venture or other Entity. 

        2.    Services of Indemnitee.    In consideration of the Company's covenants and commitments hereunder, Indemnitee
agrees to serve or continue to serve as a director of the Company. However, this Agreement shall not impose any obligation on Indemnitee or the Company to continue Indemnitee's service to the Company
beyond any period otherwise required by law or by other agreements or commitments of the parties, if any. 

        3.    Agreement to Indemnify.    The Company agrees to indemnify Indemnitee as follows: 

        (a)    Proceedings Other Than By or In the Right of the Company.    Subject to the exceptions contained in
Section 4(a) below, if Indemnitee was or is a party or is threatened to be made a party to any Proceeding (other than an action by or in the right of the Company) by reason of Indemnitee's
Corporate Status, Indemnitee shall be indemnified by the Company against all Expenses and Liabilities incurred or paid by Indemnitee in connection with such Proceeding (referred to herein as
"Indemnifiable Expenses" and "Indemnifiable Liabilities," respectively, and collectively as "Indemnifiable Amounts"). 

        (b)    Proceedings By or In the Right of the Company.    Subject to the exceptions contained in Section 4(b)
below, if Indemnitee was or is a party or is threatened to be made a party to any Proceeding by or in the right of the Company by reason of Indemnitee's Corporate Status, Indemnitee shall be
indemnified by the Company against all Indemnifiable Expenses. 

        (c)    Conclusive Presumption Regarding Standard of Care.    In making any determination required to be made under
Delaware law with respect to entitlement to indemnification hereunder, the person, persons or
entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee submitted a request therefor in accordance with Section 5 of
this Agreement, and the Company shall have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that
presumption. 

        4.    Exceptions to Indemnification.    Indemnitee shall be entitled to indemnification under Sections 3(a) and
3(b) above in all circumstances other than with respect to any specific claim, issue or matter involved in the Proceeding out of which Indemnitee's claim for indemnification has arisen, as follows: 

        (a)    Proceedings Other Than By or In the Right of the Company.    If indemnification is requested under
Section 3(a) and it has been finally adjudicated by a court of competent jurisdiction that, in connection with such specific claim, issue or matter, Indemnitee failed to act (i) in good
faith and (ii) in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, or, with respect to any criminal Proceeding, Indemnitee had reasonable
cause to believe that Indemnitee's conduct was unlawful, Indemnitee shall not be entitled to payment of Indemnifiable Amounts hereunder. 

2

 

        (b)    Proceedings By or In the Right of the Company.    If indemnification is requested under Section 3(b) and 

          (i)  it
has been finally adjudicated by a court of competent jurisdiction that, in connection with such specific claim, issue or matter, Indemnitee failed to act
(A) in good faith and (B) in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, Indemnitee shall not be entitled to payment of
Indemnifiable Expenses hereunder; or 

         (ii)  it
has been finally adjudicated by a court of competent jurisdiction that Indemnitee is liable to the Company with respect to such specific claim, Indemnitee shall not
be entitled to payment of Indemnifiable Expenses hereunder with respect to such claim, issue or matter unless the Court of Chancery or another court in which such Proceeding was brought shall
determine upon application that, despite the adjudication of liability, but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such
Indemnifiable Expenses which such court shall deem proper; or 

        (iii)  it
has been finally adjudicated by a court of competent jurisdiction that Indemnitee is liable to the Company for an accounting of profits made from the purchase or
sale by the Indemnitee of securities of the Company pursuant to the provisions of Section 16(b) of the Securities Exchange Act of 1934, the rules and regulations promulgated thereunder and
amendments thereto or similar provisions of any
federal, state or local statutory law, Indemnitee shall not be entitled to payment of Indemnifiable Expenses hereunder. 

        (c)    Insurance Proceeds.    To the extent payment is actually made to the Indemnitee under a valid and collectible
insurance policy in respect of Indemnifiable Amounts in connection with such specific claim, issue or matter, Indemnitee shall not be entitled to payment of Indemnifiable Amounts hereunder except in
respect of any excess beyond the amount of payment under such insurance. 

        5.    Procedure for Payment of Indemnifiable Amounts.    Indemnitee shall submit to the Company a written request
specifying the Indemnifiable Amounts for which Indemnitee seeks payment under Section 3 of this Agreement and the basis for the claim. The Company shall pay such Indemnifiable Amounts to
Indemnitee promptly upon receipt of its request. At the request of the Company, Indemnitee shall furnish such documentation and information as are reasonably available to Indemnitee and necessary to
establish that Indemnitee is entitled to indemnification hereunder. 

        6.    Indemnification for Expenses of a Party Who is Wholly or Partly Successful.    Notwithstanding any other
provision of this Agreement, and without limiting any such provision, to the extent that Indemnitee is, by reason of Indemnitee's Corporate Status, a party to and is successful, on the merits or
otherwise, in any Proceeding, Indemnitee shall be indemnified against all Expenses reasonably incurred by Indemnitee or on Indemnitee's behalf in connection therewith. If Indemnitee is not wholly
successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee
against all Expenses reasonably incurred by Indemnitee or on Indemnitee's behalf in connection with each successfully resolved claim, issue or matter. For purposes of this Agreement, the termination
of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, by reason of settlement, judgment, order or otherwise, shall be deemed to be a successful result as to such
claim, issue or matter. 

        7.    Effect of Certain Resolutions.    Neither the settlement or termination of any Proceeding nor the failure of the
Company to award indemnification or to determine that indemnification is payable shall create a presumption that Indemnitee is not entitled to indemnification hereunder. In addition, the termination
of any proceeding by judgment, order, settlement, conviction, or upon a plea of nolo 

3

 

contendere
or its equivalent shall not create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests
of the Company or, with respect to any criminal Proceeding, had reasonable cause to believe that Indemnitee's action was unlawful. 

        8.    Agreement to Advance Expenses; Undertaking.    The Company shall advance all Expenses incurred by or on behalf
of Indemnitee in connection with any Proceeding, including a Proceeding by or in the right
of the Company, in which Indemnitee is involved by reason of such Indemnitee's Corporate Status within ten (10) calendar days after the receipt by the Company of a written statement from
Indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. To the extent required by Delaware law, Indemnitee hereby undertakes
to repay any and all of the amount of Indemnifiable Expenses paid to Indemnitee if it is finally determined by a court of competent jurisdiction that Indemnitee is not entitled under this Agreement to
indemnification with respect to such Expenses. This undertaking is an unlimited general obligation of Indemnitee. 

        9.    Procedure for Advance Payment of Expenses.    Indemnitee shall submit to the Company a written request
specifying the Indemnifiable Expenses for which Indemnitee seeks an advancement under Section 8 of this Agreement, together with documentation evidencing that Indemnitee has incurred such
Indemnifiable Expenses. Payment of Indemnifiable Expenses under Section 8 shall be made no later than ten (10) calendar days after the Company's receipt of such request. 

        10.    Remedies of Indemnitee.    

        (a)    Right to Petition Court.    In the event that Indemnitee makes a request for payment of Indemnifiable Amounts
under Sections 3 and 5 above or a request for an advancement of Indemnifiable Expenses under Sections 8 and 9 above and the Company fails to make such payment or advancement in a timely
manner pursuant to the terms of this Agreement, Indemnitee may petition the Court of Chancery to enforce the Company's obligations under this Agreement. 

        (b)    Burden of Proof.    In any judicial proceeding brought under Section 10(a) above, the Company shall have
the burden of proving that Indemnitee is not entitled to payment of Indemnifiable Amounts hereunder. 

        (c)    Expenses.    The Company agrees to reimburse Indemnitee in full for any Expenses incurred by Indemnitee in
connection with investigating, preparing for, litigating, defending or settling any action brought by Indemnitee under Section 10(a) above, or in connection with any claim or counterclaim
brought by the Company in connection therewith, whether or not Indemnitee is successful in whole or in part in connection with any such action. 

        (d)    Failure to Act Not a Defense.    The failure of the Company (including its Board of Directors or any committee
thereof, independent legal counsel, or stockholders) to make a determination concerning the permissibility of the payment of Indemnifiable Amounts or the advancement of Indemnifiable Expenses under
this Agreement shall not be a defense in any action brought under Section 10(a) above, and shall not create a presumption that such payment or advancement is not permissible. 

        11.    Defense of the Underlying Proceeding.    

        (a)    Notice by Indemnitee.    Indemnitee agrees to notify the Company promptly upon being served with any summons,
citation, subpoena, complaint, indictment, information, or other document relating to any Proceeding which may result in the payment of Indemnifiable Amounts or the advancement of Indemnifiable
Expenses hereunder; provided, however, that the failure to give any such notice shall not disqualify Indemnitee from the right, or otherwise affect in any manner any right of Indemnitee, to receive
payments of Indemnifiable Amounts or advancements 

4

 

of
Indemnifiable Expenses unless the Company's ability to defend in such Proceeding is materially and adversely prejudiced thereby. 

        (b)    Defense by Company.    Subject to the provisions of the last sentence of this Section 11(b) and of
Section 11(c) below, the Company shall have the right to defend Indemnitee in any Proceeding which may give rise to the payment of Indemnifiable Amounts hereunder; provided, however that the
Company shall notify Indemnitee of any such decision to defend within ten (10) calendar days of receipt of notice of any such Proceeding under Section 11(a) above. The Company shall not,
without the prior written consent of Indemnitee, consent to the entry of any judgment against Indemnitee or enter into any settlement or compromise which (i) includes an admission of fault of
Indemnitee or (ii) does not include, as an unconditional term thereof, the full release of Indemnitee from all liability in respect of such Proceeding, which release shall be in form and
substance reasonably satisfactory to Indemnitee. This Section 11(b) shall not apply to a Proceeding brought by Indemnitee under Section 10(a) above or pursuant to Section 19
below. 

        (c)    Indemnitee's Right to Counsel.    Notwithstanding the provisions of Section 11(b) above, if in a
Proceeding to which Indemnitee is a party by reason of Indemnitee's Corporate Status, (i) Indemnitee reasonably concludes that he or she may have separate defenses or counterclaims to assert
with respect to any issue which may not be consistent with the position of other defendants in such Proceeding, (ii) a conflict of interest or potential conflict of interest exists between
Indemnitee and the Company, or (iii) if the Company fails to assume the defense of such proceeding in a timely manner, Indemnitee shall be entitled to be represented by separate legal counsel
of Indemnitee's choice at the expense of the Company. In addition, if the Company fails to comply with any of its obligations under this Agreement or in the event that the Company or any other person
takes any action to declare this Agreement void or unenforceable, or institutes any action, suit or proceeding to deny or to recover from Indemnitee the benefits intended to be provided to Indemnitee
hereunder, Indemnitee shall have the right to retain counsel of Indemnitee's choice, at the expense of the Company, to represent Indemnitee in connection with any such matter. 

        12.    Representations and Warranties of the Company.    The Company hereby represents and warrants to Indemnitee as
follows: 

        (a)    Authority.    The Company has all necessary power and authority to enter into, and be bound by the terms of,
this Agreement, and the execution, delivery and performance of the undertakings contemplated by this Agreement have been duly authorized by the Company. 

        (b)    Enforceability.    This Agreement, when executed and delivered by the Company in accordance with the provisions
hereof, shall be a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable
bankruptcy, insolvency, moratorium, reorganization or similar laws affecting the enforcement of creditors' rights generally. 

        13.    Insurance.    The Company shall, from time to time, make the good faith determination whether or not it is
practicable for the Company to obtain and maintain a policy or policies of insurance with a reputable insurance company providing the Indemnitee with coverage for losses from wrongful acts. For so
long as Indemnitee shall remain a director of the Company and with respect to any such prior service, in all policies of director and officer liability insurance, Indemnitee shall be named as an
insured in such a manner as to provide Indemnitee the same rights and benefits as are accorded to the most favorably insured of the Company's officers and directors. Notwithstanding the foregoing, the
Company shall have no obligation to obtain or maintain such insurance if the Company determines in good faith that such insurance is not reasonably available, if the premium costs for such insurance
are disproportionate to the amount of coverage provided, or if the coverage provided by such 

5

 

insurance
is limited by exclusions so as to provide an insufficient benefit. The Company shall promptly notify Indemnitee of any good faith determination not to provide such coverage. 

        14.    Contract Rights Not Exclusive.    The rights to payment of Indemnifiable Amounts and advancement of
Indemnifiable Expenses provided by this Agreement shall be in addition to, but not exclusive of, any other rights which Indemnitee may have at any time under applicable law, the Company's Certificate
of Incorporation or By-laws, or any other agreement, vote of stockholders or directors (or a committee of directors), or otherwise, both as to action in Indemnitee's official capacity and
as to action in any other capacity as a result of Indemnitee's serving as a director of the Company. 

        15.    Successors.    This Agreement shall be (a) binding upon all successors and assigns of the Company
(including any transferee of all or a substantial portion of the business, stock and/or assets of the Company and any direct or indirect successor by merger or consolidation or otherwise by operation
of law) and (b) binding on and shall inure to the benefit of the heirs, personal representatives, executors and administrators of Indemnitee. This Agreement shall continue for the benefit of
Indemnitee and such heirs, personal representatives, executors and administrators after Indemnitee has ceased to have Corporate Status. 

        16.    Subrogation.    In the event of any payment of Indemnifiable Amounts under this Agreement, the Company shall be
subrogated to the extent of such payment to all of the rights of contribution or recovery of Indemnitee against other persons, and Indemnitee shall take, at the request of the Company, all reasonable
action necessary to secure such rights, including the execution of such documents as are necessary to enable the Company to bring suit to enforce such rights. 

        17.    Change in Law.    To the extent that a change in Delaware law (whether by statute or judicial decision) shall
permit broader indemnification or advancement of expenses than is provided under the terms of the By-laws and this Agreement, Indemnitee shall be entitled to such broader indemnification
and advancements, and this Agreement shall be deemed to be amended to such extent. 

        18.    Severability.    Whenever possible, each provision of this Agreement shall be interpreted in such a manner as
to be effective and valid under applicable law, but if any provision of this Agreement, or any clause thereof, shall be determined by a court of competent jurisdiction to be illegal, invalid or
unenforceable, in whole or in part, such provision or clause shall be limited or modified in its application to the minimum extent necessary to make such provision or clause valid, legal and
enforceable, and the remaining provisions and clauses of this Agreement shall remain fully enforceable and binding on the parties. 

        19.    Indemnitee as Plaintiff.    Except as provided in Section 10(c) of this Agreement and in the next
sentence, Indemnitee shall not be entitled to payment of Indemnifiable Amounts or advancement of Indemnifiable Expenses with respect to any Proceeding brought by Indemnitee against the Company, any
Entity which it controls, any director or officer thereof, or any third party, unless the Board of Directors of the Company has consented to the initiation of such Proceeding. This Section shall not
apply to counterclaims or affirmative defenses asserted by Indemnitee in an action brought against Indemnitee. 

        20.    Modifications and Waiver.    Except as provided in Section 17 above with respect to changes in Delaware
law which broaden the right of Indemnitee to be indemnified by the Company, no supplement, modification or amendment of this Agreement shall be binding unless executed in writing by each of the
parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement (whether or not similar), nor shall such
waiver constitute a continuing waiver. 

        21.    General Notices.    All notices, requests, demands and other communications hereunder shall be in writing and
shall be deemed to have been duly given (a) when delivered by hand, (b) when 

6

 

transmitted
by facsimile and receipt is acknowledged, or (c) if mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed: 

          (i)  If
to Indemnitee, to: 

         (ii)  If
to the Company, to: 

Helicos
BioSciences Corporation

One Kendall Square, Building 700

Cambridge, MA 02139

Facsimile No.: [                  ]

Attn: Secretary 

or
to such other address as may have been furnished in the same manner by any party to the others. 

        22.    Governing Law; Consent to Jurisdiction; Service of Process.    This Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware without regard to its rules of conflict of laws. Each of the Company and the Indemnitee hereby irrevocably and unconditionally consents
to submit to the exclusive jurisdiction of the Court of Chancery of the State of Delaware and the courts of the United States of America located in the State of Delaware (the "Delaware Courts") for
any litigation arising out of or relating to this Agreement and the transactions contemplated hereby (and agrees not to commence any litigation relating thereto except in such courts), waives any
objection to the laying of venue of any such litigation in the Delaware Courts and agrees not to plead or claim in any Delaware Court that such litigation brought therein has been brought in an
inconvenient forum. Each of the parties hereto agrees, (a) to the extent such party is not otherwise subject to service of process in the State of Delaware, to appoint and maintain an agent in
the State of Delaware as such party's agent for acceptance of legal process, and (b) that service of process may also be made on such party by prepaid certified mail with a proof of mailing
receipt validated by the United States Postal Service constituting evidence of valid service. Service made pursuant to (a) or (b) above shall have the same legal force and effect as if
served upon such party personally within the State of Delaware. For purposes of implementing the parties' agreement to appoint and maintain an agent for service of process in the State of Delaware,
each such party does hereby appoint The Corporation Trust Company, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801, as such agent and each such party hereby agrees to complete all
actions necessary for such appointment. 

[signature
page follows] 

7

        IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written. 

	

 	
 	

HELICOS BIOSCIENCES CORPORATION
	

 	
 	

By:	

 
	 	 	 	

	 	 	Name:

Title:	 
	

 	
 	

INDEMNITEE
	 	 	 	 
	

 	
 	

QuickLinks

Exhibit 10.10

INDEMNIFICATION AGREEMENTQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.11    
    

 
  EXECUTION COPY    
    

 
  AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT    
    

        AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT made this 1st day of March, 2006 by and between Helicos BioSciences Corporation, a Delaware
corporation (the "Company") and the holders of the Company's Series A Convertible Preferred Stock ("Series A Preferred Stock") whose names are set forth under the heading
"Series A Investors" on Schedule I hereto, and the holders of the Company's Series B Convertible Preferred Stock (the
"Series B Preferred Stock") whose names are set forth under the heading "Series B Investors" on Schedule I hereto (the
Series A Investors and Series B Investors being referred to collectively as the "Investors"). 

        WHEREAS,
the Series B Investors have entered into a Series B Preferred Stock Purchase Agreement dated as of the date hereof, by and among the Series B Investors and
the Company (the "Purchase Agreement") to purchase an aggregate of up to Thirty-One Million Seven Thousand Seven Hundred Fifty-Two (31,007,752) shares of Series B
Preferred Stock in one or more closings; 

        WHEREAS,
as an inducement to the Series B Investors to consummate the transactions contemplated by the Purchase Agreement, the Company and the holders of a majority of the
Restricted Stock (as defined herein) under the Investor Rights Agreement dated December 19, 2003, desire to amend and restate such agreement as provided herein. 

        NOW,
THEREFORE, in consideration of the mutual covenants herein contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
Company and the Investors agree as follows: 

        1.    Certain Definitions.    As used in this Agreement, the following terms shall have the following respective
meanings: 

        "Board of Directors" shall mean the board of directors of the Company as constituted from time to time. 

        "Charitable Reserve Shares" shall mean shares of Common Stock reserved by the Company for charitable donations to be granted by the
Company at the discretion of the Board of Directors from time to time, not to exceed in the aggregate 1,250,000 shares of Common Stock (appropriately adjusted to reflect stock splits, stock dividends,
combinations of shares and the like with respect to the Common Stock). 

        "Code" shall mean the Internal Revenue Code of 1986, as amended from time to time. 

        "Commission" shall mean the Securities and Exchange Commission, or any other federal agency at the time administering the Securities Act. 

        "Common Stock" shall mean the Common Stock, $0.001 par value, of the Company, as constituted as of the date of this Agreement. 

        "Conversion Shares" shall mean shares of Common Stock issued or issuable upon conversion of the Preferred Stock. 

        "Confidential Information" shall mean any information that is labeled as confidential, proprietary or secret which a holder of Restricted
Stock obtains from the Company pursuant to financial statements, reports and other materials provided by the Company to such holder of Restricted Stock pursuant to this Agreement or pursuant to
visitation or inspection rights granted hereunder. 

        "Exchange Act" shall mean the Securities Exchange Act of 1934, as amended, or any similar federal statute, and the rules and regulations
of the Commission thereunder, all as the same shall be in effect at the time. 

 

        "Fully-Diluted Basis" shall mean, for purposes of calculating the number of outstanding shares of capital stock of the Company at a
particular time, all shares of Common Stock outstanding at such time and all shares of Common Stock issuable upon conversion or exercise of any options or other convertible securities outstanding at
such time (including without limitation shares of Preferred Stock). 

        "Indebtedness" shall mean all obligations, which should, in accordance with generally accepted accounting principles, be classified upon
the obligor's balance sheet (or the notes thereto) as liabilities, but in any event including liabilities secured by any mortgage on property owned or acquired subject to such mortgage, whether or not
the liability secured thereby shall have been assumed, and also including all guaranties and endorsements, in respect of any such obligations of others, whether or not the same are or should be so
reflected in said balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business. 

        "Intellectual Property Rights" shall mean all of the following: (i) patents, patent applications, patent disclosures and all
related continuation, continuation-in-part, divisional, reissue, re-examination, utility, model, certificate of invention and design patents, patent applications,
registrations and applications for registrations, (ii) trademarks, service marks, trade dress, logos, tradenames, service names and corporate names and registrations and applications for
registration thereof, (iii) copyrights and registrations and applications for registration thereof, (iv) mask works and registrations and applications for registration thereof,
(v) trade secrets and confidential business information, whether patentable or nonpatentable and whether or not reduced to practice, know-how, manufacturing and product processes
and techniques, research and development information, copyrightable works, financial, marketing and business data, pricing and cost information, business and marketing plans and customer and supplier
lists and information, (vi) other proprietary rights relating to any of the foregoing (including without limitation associated goodwill and remedies against infringements thereof and rights of
protection of an interest therein under the laws of all jurisdictions) and (vii) copies and tangible embodiments thereof. 

        "Key Employee" or "Key Employees" shall mean and include the President, chief executive officer, chief financial officer, chief operating
officer and chief technology officer, or any other individual who performs a significant role in the operations of the Company as may be reasonably designated by the Board of Directors of the Company. 

        "Material Adverse Change" shall mean a material adverse change in the business, operations, affairs, or condition (financial or otherwise)
of the Company. 

        "Person or Persons" shall mean an individual, corporation, partnership, joint venture, trust, or unincorporated organization, or a
government or any agency or political subdivision thereof. 

        "Preferred Stock" shall mean (i) the Series A Preferred Stock issued pursuant to that certain Series A Purchase
Agreement dated as of December 19, 2003 between the Company and the other parties named therein and (ii) the Series B Preferred Stock issued pursuant to the Purchase Agreement. 

        "Qualified Public Offering" shall mean an underwritten public offering pursuant to an effective registration under the Securities Act
covering the offer and sale by the Company of its Common Stock on the New York Stock Exchange or the NASDAQ National Market in which the aggregate offering proceeds to the Company equal or exceed
$50 million and the per share offering price is at least $3.87 (subject to appropriate adjustment by the Company's Board of Directors in the event of any stock split or similar event). 

2

 

        "Registrable Shares" shall mean (1) the Common Stock issuable upon conversion of the Preferred Stock, (2) any Common Stock
purchased by an Investor (or its permitted transferees) pursuant to Section 12 hereof (or Common Stock issuable with respect to other securities so purchased), (3) any Common Stock of
the Company issued as a dividend or other distribution with respect to, or in exchange or in replacement of, such Preferred Stock or Common Stock, (4) 540,556 shares of Common Stock issued to
NewcoGen Group LLC upon the exercise of that certain warrant dated November 12, 2003, and (5) for the purposes of Section 5 only, Common Stock held by Stanley N. Lapidus and
Stephen R. Quake. 

        "Registration Expenses" shall mean the expenses so described in Section 8. 

        "Reserved Employee Shares" shall mean shares of Common Stock not to exceed in the aggregate 14,076,382 shares (appropriately adjusted to
reflect stock splits, stock dividends, combinations of shares and the like with respect to the Common Stock) reserved by the Company for issuance pursuant to stock purchase, stock grant or stock
option arrangements for employees, directors or consultants of the Company, all under arrangements approved by the Board of Directors. The foregoing number of Reserved Employee Shares may be increased
by vote or written consent of the Board of Directors, including in all cases the affirmative vote or consent of a majority of the directors designated by the holders of Series A Preferred
Stock. 

        "Restricted Stock" shall mean (a) all shares of Common Stock held by the Investors and (b) all Conversion Shares held by the
Investors, excluding, in the case of (a) and (b), shares which have been (i) registered under the Securities Act pursuant to an effective registration statement filed thereunder
and disposed of in accordance with the registration statement covering them or (ii) publicly sold pursuant to Rule 144 under the Securities Act. 

        "Right Holder" shall mean any holder of Registrable Shares. For the avoidance of doubt, Stanley N. Lapidus and Stephen R. Quake shall only
be deemed Right Holders for purposes of Section 5 hereof. 

        "Securities Act" shall mean the Securities Act of 1933, as amended, or any similar federal statute, and the rules and regulations of the
Commission thereunder, all as the same shall be in effect at the time. 

        "Selling Expenses" shall mean the expenses so described in Section 8. 

        "Subsidiary" or "Subsidiaries" shall mean any corporation or trust of which the Company and/or any of its other Subsidiaries (as herein
defined) directly or indirectly owns at the time outstanding shares of every class of such corporation or trust other than directors' qualifying shares comprising at least fifty percent (50%) of the
voting power of such corporation or trust. 

        2.    Restrictive Legend.    Each certificate representing Preferred Stock, Conversion Shares or Restricted Stock
shall, except as otherwise provided in this Section 2 or in Section 3, be stamped or otherwise imprinted with a legend substantially in the following form: 

        "THIS
SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR ANY STATE SECURITIES LAWS AND MAY NOT BE TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS IT HAS BEEN REGISTERED
UNDER SUCH ACT AND ALL SUCH APPLICABLE LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE." 

A
certificate shall not bear such legend if in the opinion of counsel reasonably satisfactory to the Company the securities represented thereby may be publicly sold without registration under the
Securities Act and any applicable state securities laws. 

3

 

        3.    Notice of Proposed Transfer.    Prior to any proposed transfer of any Preferred Stock, Conversion Shares or
Restricted Stock (other than under the circumstances described in Sections 4, 5 or 6), the holder thereof shall give written notice to the Company of its intention to effect such transfer. Each such
notice shall describe the manner of the proposed transfer and, if requested by the Company, shall be
accompanied by an opinion of counsel reasonably satisfactory to the Company to the effect that the proposed transfer may be effected without registration under the Securities Act and any applicable
state securities laws, whereupon the holder of such stock shall be entitled to transfer such stock in accordance with the terms of its notice; provided,  however, that no such opinion of counsel shall be required for a transfer to one or more partners or members of the transferor (in the case of a
transferor that is a partnership or a limited liability company, respectively) or to an affiliated corporation (in the case of a transferor that is a corporation) or to any family member, or to any
trust, family liability company, family limited partnership or similar estate planning entity for the benefit of any such family member of the transferor;  provided, further, however, that any
transferee other than a transferee receiving such shares for no consideration shall
execute and deliver to the Company a representation letter in form reasonably satisfactory to the Company's counsel to the effect that the transferee is acquiring such shares for its own account, for
investment purposes and without any view to distribution thereof. Each certificate for Preferred Stock, Conversion Shares or Restricted Stock transferred as above provided shall bear the legend set
forth in Section 2, except that such certificate shall not bear such legend if (i) such transfer is in accordance with the provisions of Rule 144 (or any other rule permitting
public sale without registration under the Securities Act) or (ii) the opinion of counsel referred to above is to the further effect that the transferee and any subsequent transferee (other
than an affiliate of the Company) would be entitled to transfer such securities in a public sale without registration under the Securities Act. The restrictions provided for in this Section 3
shall not apply to securities which are not required to bear the legend prescribed by Section 2 in accordance with the provisions of that Section. 

        4.    Required Registration.    

        (a)   At
any time after six months after the Company's initial public offering, Right Holders holding Registrable Shares constituting at least 50% in interest of all
Registrable Shares then outstanding may request the Company to register under the Securities Act all or any portion of the Registrable Shares held by such requesting Right Holder or Right Holders for
sale in the manner specified in such notice, provided that the reasonably anticipated aggregate price to the public of such offering would exceed $5,000,000. For purposes of this Section 4 and
Sections 5, and 6 the only securities which the Company shall be required to register shall be Registrable Shares; provided,  however, that, in any
underwritten public offering contemplated by this Section 4 or Sections 5 and 6, the holders of Preferred Stock shall be
entitled to sell such Preferred Stock to the underwriters for conversion and sale of the shares of Common Stock issued upon conversion or exercise and conversion, as applicable, thereof.
Notwithstanding anything to the contrary contained herein, no request may be made under this Section 4 within 180 days after the effective date of any registration statement on
Form S-1 filed by the Company. 

        (b)   Following
receipt of any notice under this Section 4, the Company shall immediately notify all Right Holders from whom notice has not been received and such Right
Holders shall then be entitled within 30 days thereafter to request the Company to include in the requested registration all or any portion of their Registrable Shares. The Company shall use
its best efforts to register under the Securities Act, for public sale in accordance with the method of disposition described in paragraph (a) above, the number of Registrable Shares specified
in such notice (and in all notices received by the Company from other Right Holders within 30 days after the giving of such notice by the Company). The Company shall be obligated to register
Registrable Shares pursuant to this Section 4 on two occasions only (except for on Form S-3 or any equivalent successor form);  provided, however,
that such obligation shall be deemed satisfied only when a 

4

 

registration
statement covering all Registrable Shares specified in notices received as aforesaid for sale in accordance with the method of disposition specified by the requesting Right Holders shall
have become effective or if such registration statement has been withdrawn prior to the consummation of the offering at the request of Right Holders holding a majority in interest of the Registrable
Shares to be covered by such registration statement (other than as a result of a material adverse change in the business or condition, financial or otherwise, of the Company) and, if such method of
disposition is a firm commitment underwritten public offering, all such Registrable Shares shall have been sold pursuant thereto (not including shares eligible for sale pursuant to the underwriters'
over-allotment option). 

        (c)   The
Company shall be entitled to include in any registration statement referred to in this Section 4 shares of Common Stock to be sold by the Company for its own
account, except as and to the extent that, in the opinion of the managing underwriter, such inclusion would adversely affect the marketing of the Registrable Shares to be sold. Except for registration
statements on Form S-4, S-8 or any successor thereto, the Company will not file with the Commission any other registration statement with respect to its Common Stock,
whether for its own account or that of other stockholders, from the date of receipt of a notice from requesting holders requesting sale pursuant to an underwritten offering pursuant to this
Section 4 until the date that is 180 days after completion of the period of distribution of the registration contemplated thereby. 

        5.    Incidental Registration.    If the Company at any time (other than pursuant to Section 4 or
Section 6) proposes to register any of its securities under the Securities Act for sale to the public, whether for its own account or for the account of other security holders or both (except
with respect to registration statements on Forms S-4, S-8 or another form not available for registering the Registrable Shares for sale to the public), each such time it will
give written notice to all Right Holders of its intention so to do. Upon the written request of any such Right Holder, received by the Company within 30 days after the giving of any such notice
by the Company, to register any of its Registrable Shares, the Company will use its best efforts to cause the Registrable Shares as to which registration shall have been so requested to be included in
the securities to be covered by the registration statement proposed to be filed by the Company, all to the extent requisite to permit the sale or other disposition by the holder of such Registrable
Shares so registered. In the event that any registration pursuant to this Section 5 shall be, in whole or in part, an underwritten public offering of Common Stock, the number of shares of
Common Stock to be included in such an underwriting may be reduced (first by eliminating any shares held by stockholders of the Company other than Right Holders, then by eliminating any shares which
the Company may wish to register for its own account,
and thereafter, to the extent necessary, by eliminating shares held by the Right Holders pro rata to the respective number of Registrable Shares required by the Right Holders to be included in the
registration) if and to the extent that the managing underwriter shall be of the opinion that such inclusion would adversely affect the marketing of the securities to be sold by the Company therein,
provided, however, that in no event may less than twenty percent (20%) of the total number of shares of Common Stock to be included in such underwriting
be made available for Registrable Shares unless the managing underwriter shall in good faith advise the Right Holders proposing to distribute their securities through such underwriting that such level
of participation would, in its opinion, materially adversely affect the offering price or its ability to complete the offering and shall specify the number of Registrable Shares which, in its opinion,
can be included in the registration and underwriting without such an effect. 

        6.    Registration on Form S-3.    If at any time (i) a Right Holder or Right Holders
request that the Company file a registration statement on Form S-3 or any successor thereto for a public offering of all or any portion of Registrable Shares held by such
requesting Right Holder or Right Holders which have an expected aggregate offering price of at least $1,000,000, and (ii) the Company is a registrant entitled to use Form S-3
or any successor thereto to register such shares, then the Company shall use its best efforts to register under the Securities Act on Form S-3 or any successor thereto (utilizing 

5

 

Rule 415,
if so requested), for public sale in accordance with the method of disposition specified in such notice, the number of Registrable Shares specified in such notice. Whenever the
Company is required by this Section 6 to use its best efforts to effect the registration of Registrable Shares, each of the procedures and requirements of Section 4 (including but not
limited to the requirement that the Company notify all Right Holders from whom notice has not been received and provide them with the opportunity to participate in the offering) shall apply to such
registration, provided, however, that there shall be no limitation on the number of registrations on
Form S-3 which may be requested and obtained under this Section 6, and provided,  further, however,
that the requirements contained in the first sentence of Section 4(a) shall not
apply to any registration on Form S-3 which may be requested and obtained under this Section 6. 

Notwithstanding
anything to the contrary in this Section 6, the Company shall not be required to effect more than two registrations pursuant to this Section 6 in any 12 month
period. 

        7.    Registration Procedures.    If and whenever the Company is required by the provisions of Sections 4, 5 or 6 to
use its best efforts to effect the registration of any Registrable Shares under the Securities Act, the Company will: 

        (a)   as
expeditiously as possible, prepare and file with the Commission a registration statement (which, in the case of an underwritten public offering pursuant to
Section 4, shall be on Form S-1 or other form of general applicability satisfactory to the managing underwriter selected as therein provided) with respect to such securities
and use its best efforts to cause such registration statement to
become and remain effective for the period of the distribution contemplated thereby (determined as hereinafter provided); 

        (b)   as
expeditiously as possible, prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus used in connection
therewith as may be necessary to keep such registration statement effective for the period specified in paragraph (a) above and comply with the provisions of the Securities Act with respect to
the disposition of all Registrable Shares covered by such registration statement in accordance with the sellers' intended method of disposition set forth in such registration statement for such
period; 

        (c)   furnish
to each seller of Registrable Shares and to each underwriter such number of copies of the registration statement and the prospectus included therein (including
each preliminary prospectus) as such persons reasonably may request in order to facilitate the public sale or other disposition of the Registrable Shares covered by such registration statement; 

        (d)   use
its best efforts to register or qualify the Registrable Shares covered by such registration statement under the securities or "blue sky" laws of such jurisdictions
as the sellers of Registrable Shares or, in the case of an underwritten public offering, the managing underwriter reasonably shall request, provided,  however, that the Company shall not for any such purpose be required to qualify generally to transact business as a foreign corporation in any
jurisdiction where it is not so qualified or to consent to general service of process in any such jurisdiction; 

        (e)   use
its best efforts to list the Registrable Shares covered by such registration statement with any securities exchange on which the Common Stock of the Company is then
listed; 

        (f)    provide
a transfer agent and registrar for all such Registrable Shares, not later than the effective date of such registration statement; 

        (g)   promptly
notify each seller of Registrable Shares and each underwriter under such registration statement, at any time when a prospectus relating thereto is required to
be delivered under the Securities Act, of the happening of any event of which the Company has knowledge as a result of which the prospectus contained in such registration statement, as then in effect,
includes an untrue statement of a material fact or omits to state a material fact required to be stated 

6

 

therein
or necessary to make the statements therein not misleading in light of the circumstances then existing; 

        (h)   make
available for inspection by each seller of Registrable Shares, any underwriter participating in any distribution pursuant to such registration statement, and any
attorney, accountant or other agent retained by such seller or underwriter, all financial and other records, pertinent corporate documents and properties of the Company, and cause the Company's
officers, directors and employees to supply all information reasonably requested by any such seller, underwriter, attorney, accountant or agent in connection with such registration statement. The
rights granted pursuant to this subsection (h) may not be assigned or otherwise conveyed by such person or by any subsequent transferee of any such rights without the written consent of the
Company, which consent shall not be unreasonably withheld; provided that the Company may refuse such written consent if the proposed transferee is a competitor of the Company as determined by the
Company's Board of Directors; and provided further, that no such written consent shall be required if the transfer is made to a party who is not a competitor of the Company and who is a parent,
subsidiary, affiliate, partner or group member of such person; 

        (i)    advise
each selling holder of Registrable Shares, promptly after it shall receive notice or obtain knowledge thereof, of the issuance of any stop order by the Commission
suspending the effectiveness of such registration statement or the initiation or threatening of any proceeding for such purpose and promptly use all reasonable efforts to prevent the issuance of any
stop order or to obtain its withdrawal if such stop order should be issued; 

        (j)    cooperate
with the selling holders of Registrable Shares and the managing underwriters, if any, to facilitate the timely preparation and delivery of certificates
representing Registrable Shares to be sold, such certificates to be in such denominations and registered in such names as such holders or the managing underwriters may request at least two business
days prior to any sale of Registrable Shares; and 

        (k)   permit
any holder of Registrable Shares which holder, in the judgment of the Company might be deemed to be a controlling person of the Company, to participate in good
faith in the preparation of such registration or comparable statement and to require the insertion therein of material, furnished to the Company in writing, which in the reasonable judgment of such
holder and its counsel should be included, subject to review by the Company and its counsel after consultation with such holder. 

        For
purposes of Section 7(a) and 7(b) and of Section 4(c), the period of distribution of Registrable Shares in a firm commitment underwritten public offering shall be
deemed to extend until each underwriter has completed the distribution of all securities purchased by it, and the period of distribution of Registrable Shares in any other registration shall be deemed
to extend until the earlier of the sale of all Registrable Shares covered thereby and 120 days after the effective date thereof. 

        In
connection with each registration hereunder, the sellers of Registrable Shares will furnish to the Company in writing such information with respect to themselves and the proposed
distribution by them as reasonably shall be necessary in order to assure compliance with federal and applicable state securities laws. 

        In
connection with each registration pursuant to Sections 4, 5 or 6 covering an underwritten public offering, the Company and each seller agree to enter into a written agreement with the
managing underwriter selected in the manner herein provided in such form and containing such provisions as are customary in the securities business for such an arrangement between such underwriter and
companies of the Company's size and investment stature. 

        8.    Expenses.    All expenses incurred by the Company in complying with Sections 4, 5 and 6, including, without
limitation, all registration and filing fees, printing expenses, fees and disbursements 

7

 

of
counsel and independent public accountants for the Company, fees and expenses (including counsel fees) incurred in connection with complying with state securities or "blue sky" laws, fees of the
National Association of Securities Dealers, Inc., transfer taxes, fees of transfer agents and registrars, costs of insurance, and fees and disbursements of one counsel for the sellers of
Registrable Shares, but excluding any Selling Expenses, are called "Registration Expenses". All underwriting discounts and selling commissions applicable to the sale of Registrable Shares are called
"Selling Expenses". 

        The
Company will pay all Registration Expenses in connection with each registration statement under Sections 4, 5 or 6. All Selling Expenses in connection with each registration
statement under Sections 4, 5 or 6 shall be borne by the participating sellers in proportion to the number of shares sold by each, or by such participating sellers other than the Company (except to
the extent the Company shall be a seller) as they may agree. 

        9.    Indemnification and Contribution.    

        (a)   In
the event of a registration of Registrable Shares under the Securities Act pursuant to Sections 4, 5 or 6, the Company will indemnify and hold harmless each seller of
Registrable Shares thereunder, each underwriter of Registrable Shares thereunder and each other person, if any, who controls such seller or underwriter within the meaning of the Securities Act,
against any losses, claims, damages or liabilities, joint or several, to which such seller, underwriter or controlling person may become subject under the Securities Act or otherwise, insofar as such
losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact contained in any
registration statement under which such Registrable Shares were registered under the Securities Act pursuant to Sections 4, 5 or 6, any preliminary prospectus or final prospectus contained therein, or
any amendment or supplement thereof, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the
statements therein in light of the circumstances under which they were made not misleading, and will reimburse each such seller, each such underwriter and each such controlling person for any legal or
other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action, provided,  however, that the Company will not be liable in any such case if and to the extent that any such loss, claim, damage or liability arises out of or is
based upon an untrue statement or alleged untrue statement or omission or alleged omission so
made in conformity with information furnished by any such seller, any such underwriter or any such controlling person in writing specifically for use in such registration statement or prospectus and,
provided, further, that with respect to any untrue statement or alleged untrue statement in or omission or alleged omission from any registration statement the indemnity agreement contained in this
subsection (a) shall not inure to the benefit of any holder of Registrable Shares, any underwriter or any controlling person of such holder from whom the person asserting any such losses,
claims, damages or liabilities purchased the Registrable Shares concerned, to the extent that a registration statement relating to such Registrable Shares was required to be delivered by such holder,
underwriter or controlling person under the Securities Act in connection with such purchase and any such loss, claim, damage or liability results from the fact that there was not sent or given to such
person, at or prior to the written confirmation of the sale of such Registrable Shares to such person, a copy of the final registration statement or prospectus if the Company had previously furnished
copies thereof to such holder, underwriter or controlling person. 

        (b)   In
the event of a registration of any of the Registrable Shares under the Securities Act pursuant to Sections 4, 5 or 6, each seller of Registrable Shares thereunder,
severally and not jointly, will indemnify and hold harmless the Company, each person, if any, who controls the Company within the meaning of the Securities Act, each officer of the Company who signs
the registration statement, each director of the Company, each underwriter and each person who controls any underwriter within the meaning of the Securities Act, against all losses, claims, 

8

 

damages
or liabilities, joint or several, to which the Company or such officer, director, underwriter or controlling person may become subject under the Securities Act or otherwise, insofar as such
losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact contained in the
registration statement under which such Registrable Shares were registered under the Securities Act pursuant to Sections 4, 5 or 6, any preliminary prospectus or final prospectus contained therein, or
any amendment or supplement thereof, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the
statements therein in light of the circumstances under which they were made not misleading, and will reimburse the Company and each such officer, director, underwriter and controlling person for any
legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action,  provided, however, that such seller will be liable hereunder in any such case if and only to the extent
that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity
with information pertaining to such seller, as such, furnished in writing to the Company by such seller specifically for use in such registration statement or prospectus, and  provided, further, however, that the liability of each
seller hereunder shall be limited to the proportion of any such loss, claim, damage, liability or expense which is equal to the proportion that the public offering price of the shares sold by such
seller under such registration statement bears to the total public offering price of all securities sold thereunder, but not in any event to exceed the net proceeds received by such seller from the
sale of Registrable Shares covered by such registration statement. 

        (c)   Promptly
after receipt by an indemnified party hereunder of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to
be made against the indemnifying party hereunder, notify the indemnifying party in writing thereof, but the omission so to notify the
indemnifying party shall not relieve it from any liability which it may have to such indemnified party other than under this Section 9 and shall only relieve it from any liability which it may
have to such indemnified party under this Section 9 if and to the extent the indemnifying party is prejudiced by such omission. In case any such action shall be brought against any indemnified
party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate in and, to the extent it shall wish, to assume and undertake the
defense thereof with counsel reasonably satisfactory to such indemnified party, and, after notice from the indemnifying party to such indemnified party of its election so to assume and undertake the
defense thereof, the indemnifying party shall not be liable to such indemnified party under this Section 9 for any legal expenses subsequently incurred by such indemnified party in connection
with the defense thereof other than reasonable costs of investigation and of liaison with counsel so selected, provided,  however, that, if the defendants
in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have
reasonably concluded that there may be reasonable defenses available to it which are different from or additional to those available to the indemnifying party or if the interests of the indemnified
party reasonably may be deemed to conflict with the interests of the indemnifying party, the indemnified party shall have the right to select a separate counsel and to assume such legal defenses and
otherwise to participate in the defense of such action, with the expenses and fees of such separate counsel and other expenses related to such participation to be reimbursed by the indemnifying party
as incurred. 

        (d)   In
order to provide for just and equitable contribution to joint liability under the Securities Act in any case in which either (i) any holder of Registrable
Shares exercising rights under this Agreement, or any controlling person of any such holder, makes a claim for indemnification pursuant to this Section 9 but it is judicially determined (by the
entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or 

9

 

the
denial of the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this Section 9 provides for indemnification in such case, or
(ii) contribution under the Securities Act may be required on the part of any such selling holder or any such controlling person in circumstances for which indemnification is provided under
this Section 9; then, and in each such case, the Company and such holder will contribute to the aggregate losses, claims, damages or liabilities to which they may be subject (after contribution
from others) in such proportion so that such holder is responsible for the portion represented by the percentage that the public offering price of its Registrable Shares offered by the registration
statement bears to the public offering price of all securities offered by such registration statement, and the Company is responsible for the remaining portion;  provided, however, that, in any such case, (A) no such holder will be required to contribute any
amount in excess of the public offering price of all such Registrable Shares offered by it pursuant to such registration statement; and (B) no person or entity guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person or entity who was not guilty of such fraudulent misrepresentation. 

        10.    Changes in Common Stock or Preferred Stock.    If, and as often as, there is any change in the Common Stock or
the Preferred Stock by way of a stock split, stock dividend, combination or reclassification, or through a merger, consolidation, reorganization or recapitalization, or by any other means, appropriate
adjustment shall be made in the provisions hereof so that the rights and privileges granted hereby shall continue with respect to the Common Stock and the Preferred Stock as so changed. 

        11.    Rule 144 Reporting.    With a view to making available the benefits of certain rules and regulations of
the Commission which may at any time permit the sale of the Registrable Shares to the public without registration, at all times after 90 days after any registration statement covering a public
offering of securities of the Company under the Securities Act shall have become effective, the Company agrees to: 

        (a)   make
and keep public information available, as those terms are understood and defined in Rule 144 under the Securities Act; 

        (b)   use
its best efforts to file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange
Act; and 

        (c)   furnish
to each holder of Registrable Shares forthwith upon request a written statement by the Company as to its compliance with the reporting requirements of such
Rule 144 and of the Securities Act and the Exchange Act, a copy of the most recent annual or quarterly report of the Company, and such other reports and documents so filed by the Company as
such holder may reasonably request in availing itself of any rule or regulation of the Commission allowing such holder to sell any Registrable Shares without registration. 

        12.    Right of First Refusal    

        (a)    Right of First Refusal.    The Company shall not issue, sell or exchange, agree or obligate itself to issue,
sell or exchange, any (i) shares of Common Stock, (ii) any other equity security of the Company, including without limitation, Preferred Stock, (iii) any debt security of the
Company which by its terms is convertible into or exchangeable for any equity security of the Company, or (iv) any option, warrant or other right to subscribe for, purchase or otherwise acquire
any such equity security or any such convertible debt security of the Company, unless in each case the Company shall have first offered to sell such securities (the "Offered Securities") to each
Investor holding at least 500,000 shares of Preferred Stock (subject to appropriate adjustment for stock splits, stock dividends, combinations or any other similar recapitalization affecting such
shares) (each an "Offeree" and collectively, the "Offerees") as follows: Each Offeree shall have the right 

10

 

to
purchase that portion of the Offered Securities as the number of shares of Restricted Stock then held by such Offeree bears to the total number of shares of capital stock of the Company on a Fully-
Diluted Basis (the "Offered Amount") at a price and on such other terms as shall have been specified by the Company in writing delivered to such Offeree (the "Offer"), which Offer by its terms shall
remain open and irrevocable for a period of fifteen (15) days from receipt thereof by the Offerees. 

        (b)    Notice of Acceptance.    Notice of each Offeree's intention to accept, in whole or in part, any Offer made
pursuant to Section 12(a) shall be evidenced by a writing signed by such Offeree and delivered to the Company prior to the end of the 15-day period of such offer, setting forth such
of the Offeree's Offered Amount as such Offeree elects to purchase (the "Notice of Acceptance"). 

        (c)    Conditions to Acceptances and Purchase.    

        (i)    Permitted Sales of Refused Securities.    In the event that Notices of Acceptance are not given by the Offerees
in respect of all the Offered Securities, the Company shall have ninety (90) days from the expiration of the period set forth in Section 12(a) to close the sale of all or any part of
such Offered Securities as to which a Notice of Acceptance has not been given by the Offerees (the "Refused Securities") to the Person or Persons specified in the Offer, but only for the consideration
described in the Offer and otherwise in all respects upon terms and conditions, including, without limitation, unit price and interest rates, which are no more favorable, in the aggregate, to such
other Person or Persons or less favorable to the Company than those set forth in the Offer. 

        (ii)    Reduction in Amount of Offered Securities.    In the event the Company shall propose to sell less than all the
Refused Securities (any such sale to be in the manner and on the terms specified in Section 12(c)(i) above), then each Offeree may, at its sole option and in its sole discretion, reduce
the number of shares or other units of the Offered Securities specified in its respective Notice of Acceptance to an amount which shall be not less than the amount of the Offered Securities which the
Offeree elected to purchase pursuant to Section 12(b) multiplied by a fraction, (i) the numerator of which shall be the amount of Offered Securities which the Company actually proposes
to sell, and (ii) the denominator of which shall be the amount of all Offered Securities. In the event that any Offeree so elects to reduce the number or amount of Offered Securities specified
in its respective Notice of Acceptance, the Company may not sell or otherwise dispose of more than the reduced amount of the Offered Securities until such securities have again been offered to the
Offerees in accordance with Section 12(a). 

        (iii)    Closing.    Upon the closing, which shall include full payment to the Company, of the sale to such other
Person or Persons of all or less than all the Refused Securities, the Offerees shall purchase from the Company, and the Company shall sell to the Offerees, the number of Offered Securities specified
in the Notices of Acceptance, as reduced pursuant to Section 12(c)(ii) if the Offerees have so elected, upon the terms and conditions specified in the Offer. The purchase by the Offerees
of any Offered Securities is subject in all cases to the preparation, execution and delivery by the Company and the Offerees of a purchase agreement relating to such Offered Securities reasonably
satisfactory in form and substance to the Company, the Offerees and their respective counsel. 

        (d)    Further Sale.    In each case, any Offered Securities not purchased by the Offerees or other Person or Persons
in accordance with Section 12(c) may not be sold or otherwise disposed of until they are again offered to the Offerees under the procedures specified in Sections 12(a), 12(b) and 12(c). 

11

 

        (e)    Termination of Right of First Refusal.    The rights of the Offerees under this Section 12 shall
terminate immediately prior to, but subject to, the consummation of a Qualified Public Offering; provided, however, that the rights of the Investors
pursuant to this Section 12 may be waived as to all of such Investors by the affirmative vote or written consent of Investors holding at least a majority in interest of the then outstanding
shares of Restricted Stock then held by Investors, and any such waiver shall be binding on all Investors, even if any of such Investors do not execute such waiver and irrespective of whether one or
more Investors participates in the purchase of the Offered Securities. 

        (f)    Exception.    The rights of the Investors under this Section 12 shall not apply to: 

        (i)    Common
Stock issued as a stock dividend to holders of Common Stock or upon any subdivision or combination of shares of Common Stock, 

        (ii)   Preferred
Stock issued as a dividend to holders of Preferred Stock upon any subdivision or combination of shares of Preferred Stock, 

        (iii)  the
Conversion Shares, 

        (iv)  any
Reserved Employee Shares, 

        (v)   any
Charitable Reserve Shares, 

        (vi)  any
securities issued pursuant to the acquisition of another entity by the Company by merger (whereby the Company owns no less than 51% of the voting power of such
corporation) or purchase of substantially all of such entity's stock or assets, if such acquisition is approved by the Board of Directors (which approval shall include the affirmative vote or consent
of at least a majority of the directors designated by the holders of Preferred Stock), 

        (vii) any
securities issued in connection with a strategic partnership, joint venture or other similar agreement, provided that such is approved by a majority of the Board
of Directors and such majority includes at least a majority of the directors designated by the holders of Preferred Stock, 

        (viii) any
securities to purchase Common Stock issued in connection with a bank loan or lease with a financial institution or the issuance of Common Stock upon the exercise
of any such warrant provided that such is approved by a majority of the Board of Directors and such majority includes at least a majority of the directors designated by the holders of the Preferred
Stock; 

        (ix)  200,000
shares of Common Stock issued to Stanley N. Lapidus pursuant to Section 5.6 of the Purchase Agreement; and 

        (x)   any
Series B Preferred Stock issued pursuant to the Purchase Agreement. 

        13.    Covenants of the Company.    

        (a)    Affirmative Covenants of the Company Other Than Reporting Requirements.    Without limiting any other covenants
and provisions hereof, and except to the extent the following covenants and provisions of this Section 13(a) are waived in any instance by the Investors holding at least a majority in interest
of the shares of Restricted Stock then held by Investors, the Company covenants and agrees that until the consummation of a Qualified Public Offering it will perform and observe the following
covenants and provisions, and will cause each Subsidiary, if and when such Subsidiary exists, to perform and observe such of the following covenants and provisions as are applicable to such
Subsidiary: 

        (i)    Inspection.    Permit, upon reasonable request and notice, each of the Investors who holds at least 500,000
shares of Preferred Stock (subject to appropriate adjustment for stock 

12

 

splits,
stock dividends, combinations or any other similar recapitalization affecting such shares) to examine the books of account of, and visit and inspect the properties of the Company and any
Subsidiary, to discuss the affairs, finances and accounts of the Company and any Subsidiary with any of its officers, directors or Key Employees and independent accountants, and consult with and
advise the management of the Company and any Subsidiary as to their affairs, finances and accounts, all at reasonable times during normal business hours. 

        (ii)    Budgets Approval.    Not later than 30 days prior to the commencement of each fiscal year, prepare and
submit to, and obtain the approval of a majority of the Board of Directors of, a business plan and monthly operating budgets in detail for the upcoming fiscal year (the "Annual Budget"). 

        (iii)    Meetings of Directors.    Hold meetings of the Company's Board of Directors not less than six
(6) times a year, either in person or by conference call. 

        (iv)    Expenses of Directors.    Promptly reimburse in full, each non-employee director (not including
board observers) of the Company for all of his reasonable out-of-pocket expenses incurred in attending each meeting of the Board of Directors of the Company or any committee
thereof. 

        (v)    Stock Option Plans.    Unless approved by a majority of the Board of Directors, including at least a majority
of the directors designated by the holders of Preferred Stock, the Company shall provide that all options granted or restricted stock purchased pursuant to the Company's 2003 Stock Option and
Incentive Plan, as amended, as well as each other stock option plan or stock purchase agreement involving employees, directors or consultants of the Company adopted by the Company from time to time
shall vest (A) with respect to twenty-five percent (25%) of the shares subject to such grant or purchase, one (1) year after the date of such grant or purchase and
(B) with respect to the remaining shares subject to such grant or purchase, on a monthly basis over a period of three years thereafter. 

        (vi)    Insurance.    Continue to carry insurance covering its properties and businesses customary for the type and
scope of its properties and businesses. 

        (vii)    Key Man Life Insurance.    Maintain, from a responsible and reputable insurance company or association, a
term life insurance policy on the life of Stanley N. Lapidus in the amount of $2,000,000, with proceeds payable to the Company. 

        (viii)    Directors and Officers Insurance.    Maintain directors' and officers' insurance that is satisfactory to the
holders of a majority in interest of the Preferred Stock. 

        (b)    Negative Covenants of the Company.    Without limiting any other covenants and provisions hereof, the Company
covenants and agrees that, until the consummation of a Qualified Public Offering or, while this Agreement remains outstanding, it will comply with and observe the following covenants and provisions,
and will cause each Subsidiary, if and when such Subsidiary exists, to comply with and observe such of the following covenants and provisions as are applicable to such Subsidiary, and will not,
without the written consent or waiver of either (i) a majority in interest of the holders of Preferred Stock or (ii) the vote or written consent of the Board of Directors, including, in
all cases, the affirmative
vote or consent of at least a majority of the directors designated by the holders of Preferred Stock or (iii) in the case of (v) the Compensation Committee of the Board of Directors: 

        (i)    Restrictions on Indebtedness.    Create, incur, assume or suffer to exist, or permit any Subsidiary to create,
incur, assume or suffer to exist, any liability not included in the Annual Budget with respect to Indebtedness for money borrowed which exceeds, in the aggregate, $100,000. 

13

 

        (ii)    Distributions.    Purchase, redeem, retire, or otherwise acquire for value any of its capital stock (or
rights, options or warrants to purchase such shares) now or hereafter outstanding, return any capital to its stockholders as such, or permit any Subsidiary to do any of the foregoing (such
transactions being hereinafter referred to as "Distributions"), except as specifically provided for in the Company's Certificate of Incorporation;  provided,
 however, that nothing herein contained shall prevent the Company from: 

        (A)  redeeming
any stock of a deceased stockholder out of insurance held by the Company on that stockholder's life, or 

        (B)  repurchasing
the shares of Common Stock held by officers, employees, directors or consultants of the Company which are subject to restricted stock purchase agreements
under which the Company has the option to repurchase such shares upon the occurrence of certain events, including the termination of employment, at a price not in excess of the original purchase price
paid to the Company by such officer, employee, director or consultant for such shares, 

if
in the case of any such transaction the payment can be made in compliance with the other terms of this Agreement. 

        (iii)    License of Intellectual Property.    Grant an exclusive license in or sell any of the Company's Intellectual
Property Rights which are material to the business of the Company to any Person or entity which is not a member of the consolidated group of the Company and its Subsidiaries;  provided, however, that this Section shall not apply to transfers of Intellectual Property Rights
accomplished in the ordinary course of business. 

        (iv)    Board Size.    Increase the size of the Board of Directors above (8) eight members. 

        (v)    Key Employee Compensation.    Establish or increase the compensation of, or pay any bonus (whether in cash or
equity) to, any Key Employee except as contemplated in the Company's Annual Budget or required by such Key Employee's employment agreement or offer letter. 

        (vi)    Related Transactions.    Enter into any transactions with directors, officers, employees, consultants or 5%
stockholders of the Company or their affiliates other than employment and consulting agreements in the ordinary course of business. 

        (vii)    Acquisition.    Acquire all or substantially all (including through a Company Subsidiary) of the properties,
assets or stock of any other company or entity. 

        (c)    Reporting Requirements.    Until the consummation of a Qualified Public Offering, the Company will furnish the
following to each Investor so long as such Investor holds at least 500,000 shares of Restricted Stock (subject to appropriate adjustment for stock splits, stock dividends, combinations or any other
similar recapitalization affecting such shares): 

        (i)    Monthly Reports:    as soon as available and in any event within 30 days after the end of each calendar
month, an unaudited balance sheet of the Company and its Subsidiaries as of the end of such month and statements of income and retained earnings of the Company and its Subsidiaries for such month and
for the period commencing at the end of the previous fiscal year and ending with the end of such month; 

        (ii)    Quarterly Reports:    as soon as available and in any event within 45 days after the end of each of the
first three quarters of each fiscal year of the Company, an unaudited balance sheet of the Company and its Subsidiaries as of the end of such quarter and statements of income and cash flows of the
Company and its Subsidiaries for such quarter; 

14

 

        (iii)    Annual Reports:    as soon as available and in any event within 90 days after the end of each fiscal
year of the Company, a copy of the annual audit report for such year for the Company and its Subsidiaries, including therein consolidated balance sheets of the Company and its Subsidiaries as of the
end of such fiscal year and consolidated statements of income and of the Company and its Subsidiaries for such fiscal year by independent public accountants of recognized national standing; 

        (iv)    Budgets:    as soon as available after approval by the Board of Directors and in any event within
30 days after the end of each fiscal year of the Company, the Annual Budget; 

        The
holders of Restricted Stock hereby covenant and agree that all of the information disclosed to such holders pursuant to the provisions of this Section 13(c) shall be treated
in accordance with Section 14 of this Agreement. 

        14.    Confidentiality.    Subject to the disclosure of information of a non-technical nature, including
financial information, which such holder discloses to its partners and/or shareholders generally, each holder of Restricted Stock agrees it will keep confidential and will not disclose, divulge or use
for any purpose, other than to monitor its investment in the Company, any Confidential Information, unless such Confidential Information (i) is known or becomes known to the public in general
(other than as a result of a breach of this Section 14 by such holder of Restricted Stock), (ii) is or has been independently developed or conceived by the holder of Restricted Stock
without use of the Company's Confidential Information or (iii) is or has been made known or disclosed to the holder of Restricted Stock by a third party without a breach of any obligation of
confidentiality such third party may have to the Company; provided, however, that a holder of Restricted Stock may disclose Confidential Information (a) to its attorneys, accountants,
consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company, (b) to any prospective purchaser of any
Preferred Stock from such Purchaser as long as such prospective purchaser agrees to be bound by the provisions of this Section 14, (c) to any affiliate, partner, member, stockholder or
wholly owned subsidiary of such holder of Restricted Stock, provided that such person is obligated not to disclose, divulge or use any Confidential Information to the same extent as the holders of
Restricted Stock, or (d) as may otherwise be required by law, provided that the Purchaser takes reasonable steps to minimize the extent of any such required disclosure. Notwithstanding the
foregoing, such information shall not be deemed confidential for the purpose of enforcing this Agreement. Notwithstanding anything herein to the contrary, each party to this Agreement (and each
employee, representative, or other agent of such party) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the transactions contemplated herein
and all materials of any kind (including opinions or other tax analyses) that are provided to such party relating to such tax treatment and tax structure. 

        15.    Miscellaneous.    

        (a)   All
covenants and agreements contained in this Agreement by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors
and assigns of the parties hereto (including without limitation transferees of any Preferred Stock or Restricted Stock), whether so expressed or not,  provided, however, that registration rights conferred herein on the holders of Registrable Shares shall
only inure to the benefit of a transferee of Registrable Shares if (i) there is transferred to such transferee at least 1,000,000 Registrable Shares or (ii) such transferee is a partner,
shareholder or affiliate of a party hereto. 

15

 

        (b)   All
notices, requests, consents and other communications hereunder shall be in writing and shall be delivered in person, mailed by certified or registered mail, return
receipt requested, or sent by telecopier or telex, addressed as follows: 

if
to the Company or any other party hereto, at the address of such party set forth in the Purchase Agreement; 

if
to any subsequent holder of Preferred Stock, Conversion Shares or Restricted Stock, to it at such address as may have been furnished to the Company in writing by such holder; 

or,
in any case, at such other address or addresses as shall have been furnished in writing to the Company (in the case of a holder of Preferred Stock, Conversion Shares or Restricted Stock) or to the
holders of Preferred Stock, Conversion Shares or Restricted Stock (in the case of the Company) in accordance with the provisions of this paragraph. 

        (c)   This
Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as
to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to its principles of conflicts of laws. 

        (d)   This
Agreement may not be amended or modified, and no provision hereof may be waived, without the written consent of the Company and Investors holding at least a
majority in interest of the Restricted Stock held by Investors. 

        (e)   This
Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same
instrument. 

        (f)    The
obligations of the Company to register shares of Restricted Stock under Sections 4, 5 or 6 shall terminate on the fifth anniversary of the date of a Qualified Public
Offering. 

        (g)   If
requested in writing by the underwriters for the initial underwritten public offering of securities of the Company, each holder of Restricted Stock who is a party to
this Agreement shall agree not to sell publicly any shares of Restricted Stock or any other shares of Common Stock (other than shares of Restricted Stock or other shares of Common Stock being
registered in such offering), without the consent of such underwriters, for a period not to exceed 180 days following the effective date of the registration statement relating to such offering;  provided, however, that all persons entitled to
registration rights with respect to shares of Common Stock who are not parties to this Agreement, all other persons selling shares of Common Stock in such offering, all persons holding in excess of 1%
of the capital stock of the Company on a Fully-Diluted Basis and all executive officers and directors of the Company shall also have agreed not to sell publicly their Common Stock under the
circumstances and pursuant to the terms set forth in this Section 15(g). 

        (h)   Notwithstanding
the provisions of Section 7(a), the Company's obligation to file a registration statement, or cause such registration statement to become
and remain effective, shall be suspended for a period not to exceed 90 days in any 12-month period if the Company shall furnish to the Right Holders a certificate signed by the
President of the Company stating that in the good faith judgment of the Board of Directors it would be seriously detrimental to the Company or its stockholders for a registration statement to be filed
in the near future. 

        (i)    Without
the prior written consent of the holders of at least a majority in voting power of then outstanding Registrable Shares held by Investors, the Company shall not
grant rights to any person or entity: (a) to cause the Company to register any of such person's or entity's securities of the Company; (b) to include such person's or entity's securities
of the Company in any registration statement filed under Section 4 or Section 6 hereof; (c) to include such person's or entity's securities of the Corporation in any registration
statement described in Section 5 hereof, unless under the terms of such agreement, such person or entity may include such securities in any such 

16

 

registration
only to the extent that the inclusion of his or its securities will not reduce the amount of Registrable Shares of the Right Holders which is included in such registration; or
(d) otherwise to cause the registration of such person's or entity's securities of the Company in any manner which are superior to or pari passu
with the registration rights granted herein to the Right Holders. 

        (j)    If
any provision of this Agreement shall be held to be illegal, invalid or unenforceable, such illegality, invalidity or unenforceability shall attach only to such
provision and shall not in any manner affect or render illegal, invalid or unenforceable any other provision of this Agreement, and this Agreement shall be carried out as if any such illegal, invalid
or unenforceable provision were not contained herein. 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK] 

17

        Please indicate your acceptance of the foregoing by signing and returning the enclosed counterpart of this letter, whereupon this Agreement shall be a binding agreement between the
Company and you. 

	

 	
 	

Very truly yours,
	

 	
 	

HELICOS BIOSCIENCES CORPORATION
	

 	
 	

By:	

/s/ Stanley N. Lapidus
	 	 	 	

	 	 	Name:	Stanley N. Lapidus
	 	 	Title:	President

AGREED
TO AND ACCEPTED as of the date first above written. 

INVESTORS:

NEWCOGEN
GROUP LLC;

NEWCOGEN EQUITY INVESTORS LLC;

NEWCOGEN PE LLC;

NEWCOGEN ÉLAN LLC;

ST NEWCOGEN LLC;

NEWCOGEN LONG REIGN HOLDING LLC 

Each
by its Manager NewcoGen Group Inc. 

	

By:	

/s/ Noubar B. Afeyan	
 	

 
	 	
	 	 
	 	Noubar B. Afeyan

President	 	 
	

APPLIED GENOMIC TECHNOLOGY CAPITAL FUND, L.P.;

AGTC ADVISORS FUND, L.P.
	

Each by its General Partner, AGTC Partners, L.P.

By its General Partner, NewcoGen Group Inc.
	

By:	

/s/ Noubar B. Afeyan	
 	

 
	 	
	 	 
	 	Noubar B. Afeyan

President	 	 
	

FLAGSHIP VENTURES FUND 2004, L.P.
	

By:	

Flagship Ventures General Partner LLC,

its General Partner	
 	

 
	

By:	

/s/ Noubar B. Afeyan	
 	

 
	 	
	 	 
	Name:

Title:	 	 

AGREED
TO AND ACCEPTED as of the date first above written. 

ATLAS
VENTURE FUND V, L.P.

ATLAS VENTURE PARALLEL FUND V-A, C.V.

ATLAS VENTURE ENTREPRENEURS' FUND V, L.P. 

	By:	Atlas Venture Associates V, L.P.

their general partner	 	 
	By:	Atlas Venture Associates V, Inc.

its general partner	 	 
	

/s/ ILLEGIBLE
 Vice President	
 	

 
	

ATLAS VENTURE FUND VI, L.P.

ATLAS VENTURE ENTREPRENEURS' FUND VI, L.P.
	

By:	

Atlas Venture Associates VI, L.P.

their general partner	
 	

 
	By:	Atlas Venture Associates VI, Inc.

its general partner	 	 
	

/s/ ILLEGIBLE
 Vice President	
 	

 
	

ATLAS VENTURE FUND VI GMBH & CO. KG
	

By:	

Atlas Venture Associates VI, L.P.

its managing limited partner	
 	

 
	By:	Atlas Venture Associates VI, Inc.

its general partner	 	 
	

/s/ ILLEGIBLE
 Vice President	
 	

 

AGREED
TO AND ACCEPTED as of the date first above written. 

MPM
BIOVENTURES III, L.P. 

	By:	MPM BioVentures III GP, L.P., its General Partner
	By:	MPM BioVentures III LLC, its General Partner
	

By:	

/s/ Ansbert Gadicke	
 	

 
	 	
	 	 
	Name:	Ansbert Gadicke	 	 
	Title:	Series A Member	 	 
	

MPM BIOVENTURES III-QP, L.P.
	

By:	

MPM BioVentures III GP, L.P., its General Partner
	By:	MPM BioVentures III LLC, its General Partner
	

By:	

/s/ Ansbert Gadicke	
 	

 
	 	
	 	 
	Name:	Ansbert Gadicke	 	 
	Title:	Series A Member	 	 
	

MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG
	

By:	

MPM BioVentures III GP, L.P., in its capacity as the Managing Limited Partner
	By:	MPM BioVentures III LLC, its General Partner
	

By:	

/s/ Ansbert Gadicke	
 	

 
	 	
	 	 
	Name:	Ansbert Gadicke	 	 
	Title:	Series A Member	 	 
	

MPM BIOVENTURES III PARALLEL FUND, L.P.
	

By:	

MPM BioVentures III GP, L.P., its General Partner
	By:	MPM BioVentures III LLC, its General Partner
	

By:	

/s/ Ansbert Gadicke	
 	

 
	 	
	 	 
	Name:	Ansbert Gadicke	 	 
	Title:	Series A Member	 	 

AGREED
TO AND ACCEPTED as of the date first above written. 

MPM
ASSET MANAGEMENT INVESTORS 2003 BVIII LLC 

	By:	/s/ Ansbert Gadicke	 	 
	 	
	 	 
	Name: Ansbert Gadicke

Title: Manager

	 	 

AGREED
TO AND ACCEPTED as of the date first above written. 

HIGHLAND
CAPITAL PARTNERS VI LIMITED PARTNERSHIP 

	By:	Highland Management Partners VI Limited Partnership, its General Partner
	By:	Highland Management Partners VI, Inc., its General Partner
	

By:	

/s/ ILLEGIBLE	
 	

 
	 	
	 	 
	 	Authorized Officer	 	 
	

HIGHLAND CAPITAL PARTNERS VI-B LIMITED PARTNERSHIP
	

By:	

Highland Management Partners VI Limited Partnership, its General Partner	
 	

 
	By:	Highland Management Partners VI, Inc., its General Partner	 	 
	

By:	

/s/ ILLEGIBLE	
 	

 
	 	
	 	 
	 	Authorized Officer	 	 
	

HIGHLAND ENTREPRENEURS' FUND VI LIMITED PARTNERSHIP
	

By:	

HEF VI Limited Partnership, its General Partner
	By:	Highland Management Partners VI, Inc., its General Partner
	

By:	

/s/ ILLEGIBLE	
 	

 
	 	
	 	 
	 	Authorized Officer	 	 

AGREED
TO AND ACCEPTED as of the date first above written. 

VERSANT
VENTURE CAPITAL II, L.P. 

	By:	Versant Ventures II, LLC,

Its General Partner	 	 
	

By:	

/s/ Brian G. Atwood	
 	

 
	 	
 Brian G. Atwood

Managing Director	 	 
	

VERSANT SIDE FUND II, L.P.
	

By:	

Versant Ventures II, LLC,

Its General Partner	
 	

 
	

By:	

/s/ Brian G. Atwood	
 	

 
	 	
 Brian G. Atwood

Managing Director	 	 
	

VERSANT AFFILIATES FUND II-A, L.P.
	

By:	

Versant Ventures II, LLC,

Its General Partner	
 	

 
	

By:	

/s/ Brian G. Atwood	
 	

 
	 	
 Brian G. Atwood

Managing Director	 	 

AGREED
TO AND ACCEPTED as of the date first above written. 

	

/s/ David Shaw	
 	

 
	
 David Shaw	 	 
	

/s/ Ted Ashford	
 	

 
	
 Ted Ashford	 	 
	

/s/ Joel Adams	
 	

 
	
 Joel Adams	 	 
	

/s/ Richard S. Sanders	
 	

 
	
 Richard S. Sanders	 	 

AGREED
TO AND ACCEPTED as of the date first above written. 

	

/s/ Stanley N. Lapidus	
 	

 
	
 Stanley N. Lapidus	 	 

 
 

SCHEDULE I    
    

 
 

SCHEDULE OF INVESTORS    
    

	SERIES A INVESTORS
 
	 	No. of Shares of

Series A Convertible

Preferred Stock

	NewcoGen Group LLC	 	522,720
	NewcoGen Equity Investors LLC	 	654,631
	NewcoGen Elan LLC	 	128,215
	ST NewcoGen LLC	 	26,497
	NewcoGen PE LLC	 	136,373
	NewcoGen-Long Reign Holding LLC	 	26,643
	Applied Genomic Technology Capital Fund, L.P.	 	4,934,510
	AGTC Advisors Fund, L.P.	 	298,268
	Atlas Venture Fund V, L.P.	 	1,654,532
	Atlas Venture Parallel Fund V-A, C.V.	 	411,038
	Atlas Venture Entrepreneurs' Fund V, L.P	 	27,541
	Atlas Venture Fund VI, L.P.	 	2,993,321
	Atlas Venture Fund VI—GmbH & Co. KG	 	54,809
	Atlas Venture Entrepreneurs' Fund VI, L.P.	 	91,537
	MPM BioVentures III, LP	 	292,878
	MPM BioVentures III-QP, LP	 	4,355,885
	MPM BioVentures III GmbH & Co. Beteiligungs KG	 	368,126
	MPM BioVentures III Parallel Fund, LP	 	131,552
	MPM Asset Management Investors 2003 BVIII LLC	 	84,337
	Highland Capital Partners VI Limited Partnership	 	3,275,719
	Highland Capital Partners VI-B Limited Partnership	 	1,794,843
	Highland Entrepreneurs' Fund VI Limited Partnership	 	162,216
	Versant Venture Capital II, L.P.	 	5,090,673
	Versant Affiliates Fund II-A, L.P.	 	96,607
	Versant Side Fund II, L.P.	 	45,498
	WS Investment Company, LLC	 	104,656
	Stanley N. Lapidus	 	104,656
	David Shaw	 	52,328
	Ted Pitcher	 	52,328
	Ted Ashford	 	83,723
	Joel Adams	 	52,328
	Rick Blume	 	52,328
	Joe Jacobson	 	20,930
	TOTAL:	 	28,182,246

	SERIES B INVESTORS
 
	 	No. of Shares of

Series B Convertible

Preferred Stock

	NewcoGen Equity Investors LLC;	 	130,473
	NewcoGen PE LLC;	 	27,180
	NewcoGen Élan LLC;	 	25,554
	ST NewcoGen LLC;	 	5,281
	NewcoGen Long Reign Holding LLC	 	5,310
	Applied Genomic Technology Capital Fund, L.P.	 	1,491,028
	AGTC Advisors Fund, L.P.	 	90,126
	Flagship Ventures Fund 2004, L.P.	 	1,581,153
	Atlas Venture Fund V, L.P.	 	1,061,154
	Atlas Venture Parallel Fund V-A, C.V.	 	263,624
	Atlas Venture Entrepreneurs' Fund V, L.P	 	17,664
	Atlas Venture Fund VI, L.P.	 	1,919,801
	Atlas Venture Fund VI — GmbH & Co. KG	 	35,153
	Atlas Venture Entrepreneurs' Fund VI, L.P.	 	58,709
	MPM BioVentures III, L.P.	 	187,841
	MPM BioVentures III-QP, L.P.	 	2,793,698
	MPM BioVentures III GmbH & CO. Beteiligungs KG	 	236,102
	MPM BioVentures III Parallel Fund, L.P.	 	84,373
	MPM Asset Management Investors 2003	 	54,090
	Highland Capital Partners VI Limited Partnership	 	2,100,502
	Highland Capital Partners VI-B Limited Partnership	 	1,151,563
	Highland Entrepreneurs' Fund VI Limited Partnership	 	104,039
	Versant Venture Capital II, L.P.	 	1,885,355
	Versant Affiliates Fund II-A, L.P.	 	35,779
	Versant Side Fund II, L.P.	 	16,850
	Stanley N. Lapidus	 	58,140
	David Shaw	 	9,690
	Ted Ashford	 	31,008
	Joel Adams	 	38,760
	Richard S. Sanders	 	3,876
	TOTAL:	 	15,503,876

QuickLinks

Exhibit 10.11

EXECUTION COPY

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

SCHEDULE I

SCHEDULE OF INVESTORS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00118-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00118-of-00352.parquet"}]]